• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection.

作者信息

Conway Francesca M, Bloom Chloe I, Shah Pallav L

机构信息

Royal Brompton Hospital, London, United Kingdom.

Chelsea & Westminster Hospital, London, United Kingdom; and.

出版信息

Am J Respir Crit Care Med. 2022 Sep 15;206(6):696-703. doi: 10.1164/rccm.202111-2547PP.

DOI:10.1164/rccm.202111-2547PP
PMID:35549839
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9799128/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d21/9799128/e56cab09fdc2/rccm.202111-2547PPf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d21/9799128/e56cab09fdc2/rccm.202111-2547PPf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d21/9799128/e56cab09fdc2/rccm.202111-2547PPf1.jpg

相似文献

1
Susceptibility of Patients with Airway Disease to SARS-CoV-2 Infection.气道疾病患者对SARS-CoV-2感染的易感性。
Am J Respir Crit Care Med. 2022 Sep 15;206(6):696-703. doi: 10.1164/rccm.202111-2547PP.
2
Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study.过敏疾病与 COVID-19 的易感性和严重程度：一项全国性队列研究。
J Allergy Clin Immunol. 2020 Oct;146(4):790-798. doi: 10.1016/j.jaci.2020.08.008. Epub 2020 Aug 15.
3
Progression to a severe form of COVID-19 among patients with chronic respiratory diseases.慢性呼吸系统疾病患者向 COVID-19 严重形式的进展。
Respir Med Res. 2022 May;81:100880. doi: 10.1016/j.resmer.2021.100880. Epub 2021 Dec 30.
4
Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions.新型冠状病毒病 2019 与哮喘、变应性鼻炎：分子机制与宿主-环境相互作用。
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):1-7. doi: 10.1097/ACI.0000000000000699.
5
Asthma and COVID-19 pandemic: focus on the eosinophil count and ACE2 expression.哮喘与 COVID-19 大流行：关注嗜酸性粒细胞计数和 ACE2 表达。
Eur Ann Allergy Clin Immunol. 2022 Nov;54(6):284-289. doi: 10.23822/EurAnnACI.1764-1489.233. Epub 2021 Sep 10.
6
The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society.日本呼吸学会的全国性调查：COVID-19 患者合并呼吸道疾病的患病率，以及第一波疫情期间的死亡率。
Respir Investig. 2021 Sep;59(5):679-682. doi: 10.1016/j.resinv.2021.06.008. Epub 2021 Jul 15.
7
SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.严重哮喘患者接受生物制剂治疗后感染 SARS-CoV-2。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2588-2595. doi: 10.1016/j.jaip.2022.05.041. Epub 2022 Jun 23.
8
Asthma Associated Cytokines Regulate the Expression of SARS-CoV-2 Receptor ACE2 in the Lung Tissue of Asthmatic Patients.哮喘相关细胞因子调节哮喘患者肺部组织中 SARS-CoV-2 受体 ACE2 的表达。
Front Immunol. 2022 Jan 17;12:796094. doi: 10.3389/fimmu.2021.796094. eCollection 2021.
9
[Asthma and COVID-19].[哮喘与2019冠状病毒病]
Rev Alerg Mex. 2022;69 Suppl 1:s15-s23. doi: 10.29262/ram.v69iSupl1.1009.
10
Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.为何 COVID-19 患者的哮喘发病率较低，这证明了将 EDTA 溶液重新用于预防和治疗 COVID-19 疾病是合理的。
Med Hypotheses. 2020 Nov;144:110027. doi: 10.1016/j.mehy.2020.110027. Epub 2020 Jun 26.

引用本文的文献

1
Risk factors and effectiveness of vaccination for nosocomial SARS-CoV-2 acquisition throughout the SARS-CoV-2 pandemic.在整个新冠疫情期间，医院获得性新冠病毒感染的风险因素及疫苗接种效果。
BMC Infect Dis. 2025 Aug 19;25(1):1040. doi: 10.1186/s12879-025-11349-9.
2
Divergent responses to SARS-CoV-2 infection in bronchial epithelium with pre-existing respiratory diseases.患有既往呼吸系统疾病的支气管上皮细胞对SARS-CoV-2感染的不同反应。
iScience. 2025 Feb 12;28(3):111999. doi: 10.1016/j.isci.2025.111999. eCollection 2025 Mar 21.
3
SARS-CoV-2 Lurking and Lingering in the Depths of Lungs.

本文引用的文献

1
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial.吸入用及鼻内用环索奈德治疗成人门诊患者 COVID-19：CONTAIN 二期随机对照试验。
BMJ. 2021 Nov 2;375:e068060. doi: 10.1136/bmj-2021-068060.
2
Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study.哮喘表型与 COVID-19 风险：基于人群的观察性研究。
Am J Respir Crit Care Med. 2022 Jan 1;205(1):36-45. doi: 10.1164/rccm.202107-1704OC.
3
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
严重急性呼吸综合征冠状病毒2潜伏并 lingering 在肺部深处。（注：原英文中“lingering”这个词有误，正确拼写应该是“lingering”，意思是“徘徊、逗留”，这里结合语境意译为“留存”更合适） 正确译文：严重急性呼吸综合征冠状病毒2潜伏并留存于肺部深处。
Am J Respir Crit Care Med. 2024 Apr 1;209(7):779-780. doi: 10.1164/rccm.202401-0067ED.
4
Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.慢性阻塞性肺疾病和哮喘患者接种新冠病毒灭活疫苗和mRNA疫苗后的有效性及呼吸道不良事件：一项基于中国人群的研究
Drug Saf. 2024 Feb;47(2):135-146. doi: 10.1007/s40264-023-01364-7. Epub 2023 Dec 12.
5
Disparities in outcomes of COVID-19 hospitalizations in native American individuals.美国原住民个体 COVID-19 住院治疗结果的差异。
Front Public Health. 2023 Aug 15;11:1220582. doi: 10.3389/fpubh.2023.1220582. eCollection 2023.
6
Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases.慢性呼吸系统疾病患者对新冠灭活疫苗的免疫应答降低。
Int J Med Sci. 2023 Apr 23;20(6):737-748. doi: 10.7150/ijms.78766. eCollection 2023.
7
Outcomes and risk factors with COVID-19 or influenza in hospitalized asthma patients.住院哮喘患者 COVID-19 或流感的结局和风险因素。
Respir Res. 2022 Dec 13;23(1):342. doi: 10.1186/s12931-022-02265-6.
8
Recent developments in the immunopathology of COVID-19.COVID-19 免疫病理学的最新进展。
Allergy. 2023 Feb;78(2):369-388. doi: 10.1111/all.15593. Epub 2022 Dec 5.
9
COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics.新型冠状病毒肺炎疫苗与病毒：对药物代谢动力学和药物代谢的影响。
Drug Metab Dispos. 2023 Jan;51(1):130-141. doi: 10.1124/dmd.122.000934. Epub 2022 Oct 23.
10
Susceptibility of Patients with Asthma to a Poor Outcome of COVID-19.哮喘患者感染新冠病毒后预后不良的易感性。
Am J Respir Crit Care Med. 2022 Oct 1;206(7):922-923. doi: 10.1164/rccm.202205-0978LE.
在英国社区中有并发症高风险的人群中使用布地奈德吸入剂治疗 COVID-19（PRINCIPLE）：一项随机、对照、开放标签、适应性平台试验。
Lancet. 2021 Sep 4;398(10303):843-855. doi: 10.1016/S0140-6736(21)01744-X. Epub 2021 Aug 10.
4
Biologics may have a beneficial effect in asthma patients with COVID-19.生物制剂可能对 COVID-19 哮喘患者有益。
Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.01076-2021. Print 2021 Aug.
5
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.COVID-19 风险和结局在接受生物制剂或全身皮质类固醇治疗的成年哮喘患者中的：全国真实世界证据。
J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15.
6
Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study.慢性呼吸系统疾病是 COVID-19 住院患者发生严重结局的预测因素：一项全国性研究。
Eur Respir J. 2021 Dec 9;58(6). doi: 10.1183/13993003.04474-2020. Print 2021 Dec.
7
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.吸入用布地奈德治疗早期 COVID-19（STOIC）：一项 2 期、开放标签、随机对照试验。
Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.
8
Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study.预先存在的呼吸道疾病及其治疗与 COVID-19 重症之间的关联：一项人群队列研究。
Lancet Respir Med. 2021 Aug;9(8):909-923. doi: 10.1016/S2213-2600(21)00095-3. Epub 2021 Apr 1.
9
Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial.吸入性皮质类固醇下调 COPD 中与 SARS-CoV-2 相关的基因：一项随机对照试验的结果。
Eur Respir J. 2021 Jul 29;58(1). doi: 10.1183/13993003.00130-2021. Print 2021 Jul.
10
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.COVID-19 住院患者伴有基础呼吸系统疾病的不良结局风险：一项全国性、多中心前瞻性队列研究，使用 ISARIC WHO 临床特征化方案 UK。
Lancet Respir Med. 2021 Jul;9(7):699-711. doi: 10.1016/S2213-2600(21)00013-8. Epub 2021 Mar 4.